MRP1抑制剂增加缺氧条件下[18F]FMISO的蓄积
本研究在FaDu人头颈鳞癌细胞与荷瘤小鼠中评估多药耐药相关蛋白1(MRP1)抑制剂对[18F]FMISO PET显像的影响。体外实验显示MRP1抑制剂预处理后细胞放射性显著升高(p<0.01);体内PET显示抑制剂组肿瘤SUVmean比值显著高于对照组(p<0.05)。提示[18F]FMISO PET显像可受MRP1抑制剂影响,且不依赖缺氧状态。
要点
- MRP1抑制剂可显著增加缺氧细胞对[18F]FMISO的摄取。
- 荷瘤小鼠中MRP1抑制剂使肿瘤SUVmean比值显著升高。
- [18F]FMISO PET结果解读需考虑MRP1抑制剂的影响。
核心结论
- MRP1抑制剂增加缺氧细胞中[18F]FMISO的蓄积,提示[18F]FMISO PET显像受MRP1抑制剂影响且独立于缺氧状态。
研究设计与样本
- 体外使用FaDu人头颈鳞癌细胞,经MRP1抑制剂预处理1小时后在缺氧下与[18F]FMISO孵育4小时并测放射性。
- 体内使用FaDu荷瘤小鼠,注射[18F]FMISO后4小时行PET/CT(第1次扫描),两天后经MRP1抑制剂预处理1小时再行PET/CT(第2次扫描)。
主要发现
- MRP1抑制剂预处理的FaDu细胞放射性显著高于未处理组:环孢素A 6.91±0.27、拉帕替尼10.03±0.47、MK-571 10.15±0.44 %dose/mg protein,p<0.01。
- 荷瘤小鼠肿瘤SUVmean比值(第2次/第1次PET)在抑制剂组显著高于对照组:环孢素A 2.6±0.7、拉帕替尼2.2±0.7、MK-571 2.2±0.7、对照1.2±0.2,p<0.05。
临床怎么用
- 解读[18F]FMISO PET缺氧显像时,应关注患者是否使用MRP1抑制剂,以避免将药物导致的摄取增高误判为缺氧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: [18F]Fluoromisonidazole ([18F]FMISO) is a PET imaging probe widely used for the detection of hypoxia. We previously reported that [18F]FMISO is metabolized to the glutathione conjugate of the reduced form in hypoxic cells. In addition, we found that the [18F]FMISO uptake level varied depending on the cellular glutathione conjugation and excretion ability such as enzyme activity of glutathione-S-transferase and expression levels of multidrug resistance-associated protein 1 (MRP1, an efflux transporter), in addition to the cellular hypoxic state. In this study, we evaluated whether MRP1 activity affected [18F]FMISO PET imaging. METHODS: FaDu human pharyngeal squamous cell carcinoma cells were pretreated with MRP1 inhibitors (cyclosporine A, lapatinib, or MK-571) for 1 h, incubated with [18F]FMISO for 4 h under hypoxia, and their radioactivity was then measured. FaDu tumor-bearing mice were intravenously injected with [18F]FMISO, and PET/CT images were acquired at 4 h post-injection (1st PET scan). Two days later, the same mice were pretreated with MRP1 inhibitors (cyclosporine A, lapatinib, or MK-571) for 1 h, and PET/CT images were acquired (2nd PET scan). RESULTS: FaDu cells pretreated with MRP1 inhibitors exhibited significantly higher radioactivity than those without inhibitor treatment (cyclosporine A: 6.91 ± 0.27, lapatinib: 10.03 ± 0.47, MK-571: 10.15 ± 0.44%dose/mg protein, p < 0.01). In the in vivo PET study, the SUVmean ratio in tumors [calculated as after treatment (2nd PET scan)/before treatment of MRP1 inhibitors (1st PET scan)] of the mice treated with MRP1 inhibitors was significantly higher than those of control mice (cyclosporine A: 2.6 ± 0.7, lapatinib: 2.2 ± 0.7, MK-571: 2.2 ± 0.7, control: 1.2 ± 0.2, p < 0.05). CONCLUSION: In this study, we revealed that MRP1 inhibitors increase [18F]FMISO accumulation in hypoxic cells. This suggests that [18F]FMISO-PET imaging is affected by MRP1 inhibitors independent of the hypoxic state.
引用
- Shimizu Y, Nakai Y, Watanabe H, et al. Increased [18F]FMISO accumulation under hypoxia by multidrug-resistant protein 1 inhibitors. EJNMMI Res. 2021. PMID: 33492449. doi:10.1186/s13550-021-00752-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。